Bedtime, body mass index and obesity risk in preschool-aged children

Melyssa Roy1, Jillian J Haszard2, Jennifer S Savage3

  • 1Department of Medicine, University of Otago, Dunedin, New Zealand.

Pediatric Obesity
|May 7, 2020
PubMed

Insights

Bedtime alone is inconsistently linked to childhood obesity. However, longer sleep duration, regardless of bedtime, was associated with lower obesity risk in young children.

Area of Science:

  • Pediatric Health
  • Sleep Science
  • Obesity Research

Background:

  • Sleep duration is a known risk factor for childhood obesity.
  • Limited research exists on the impact of specific sleep aspects, like bedtime, on obesity risk in young children.

Purpose of the Study:

  • To investigate the association between bedtime and body mass index (BMI) z-score or obesity risk in children aged 2 to 5 years.
  • To determine if these associations are independent of total sleep duration.

Main Methods:

  • Utilized data from three early life obesity prevention trials and one longitudinal cohort study, including 1642 children.
  • Assessed bedtime via questionnaire and BMI through clinical measurements between ages 2 and 5 years.
  • Employed adjusted regression models and a discrete mixture model to analyze BMI z-score, obesity risk, and sleep trajectory groups.

Main Results:

  • Bedtime showed inconsistent associations with BMI z-score.
  • Later bedtimes were linked to increased obesity odds at ages 3 and 5, but this effect diminished after adjusting for sleep duration.
  • Longer nocturnal sleep duration at age 2 and longer 24-hour sleep duration at age 3 (in girls) were associated with lower obesity odds.

Conclusions:

  • The timing of bedtime appears to have an inconsistent relationship with obesity in young children.
  • This association may be mediated by its influence on overall sleep duration, with longer sleep being protective against obesity.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
162
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
180
Bulimia Nervosa01:30

Bulimia Nervosa

Bulimia nervosa is a complex and severe eating disorder characterized by a cyclical pattern of binge-and-purge eating pattern. It generally involves an episode of binge eating, followed by compensatory behaviors such as vomiting, excessive exercise, laxative use, or fasting, to prevent weight gain. Despite often maintaining a normal weight, individuals with bulimia are intensely preoccupied with their body image and harbor an overwhelming fear of gaining weight. This can contribute to the...
575
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
115
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
170